Compare GE Aerospace (GE) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GE Aerospace vs Sanofi SA — how do they compare? GE Aerospace trades at $308.2 (market cap $317.10B), while Sanofi SA trades at $40.07 (market cap $95.18B). The key difference: GE Aerospace is far larger — about 3.3× Sanofi SA's market cap, and Sanofi SA pays the higher dividend (6.01%). Which is the better fit depends on your goals — on Pluang, investors hold GE Aerospace for 111 Days and Sanofi SA for 94 Days on average.
| GE | SNY | |
|---|---|---|
Market Cap | $317.10B | $95.18B |
Volume | 6,320,106 | 2,995,646 |
Sector | Industrials | Health |
52-Week High | $381.22 | $52.34 |
52-Week Low | $273.25 | $39.51 |
Typical Hold Time | 111 Days | 94 Days |
Enterprise Value | $326.91B | $114.48B |
Dividend Yield | 0.62% | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GE Aerospace (GE) trades at $305.62, up 0.66% on the day, but faces a near-term bearish technical signal despite strong fundamentals. The company reported robust earnings beats in recent quarters, with Q2 2026 EPS of $2.02 exceeding the $1.86 estimate. Revenue growth is accelerating, reaching $45.86 billion in 2025, while net income margins improved to 17.72%. However, the stock's high valuation multiples, including a P/E of 36.04, and a significant $12 billion acquisition of Consolidated Precision Products, present both opportunity and scrutiny.
The outlook remains positive driven by strong defense demand and shareholder returns, including a $20 billion buyback and raised dividend. Analyst consensus is strongly bullish with a $409.60 price target, though risks include integration challenges from the CPP deal, cost pressures, and high debt levels. The stock's current price is approximately 25% below the consensus target, suggesting potential upside if execution risks are managed.
Sanofi (SNY) trades at $40.23, up 0.07% with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported strong Q2 2026 earnings beat with EPS of $1.21 versus $1.10 expected, continuing a trend of exceeding expectations. Recent expansion of the immunology alliance with Regeneron adds potential for future growth through new antibody programs.
While valuation metrics appear reasonable with P/E of 22.14 and P/S of 1.77, projected 2026 net income decline to $4.0B (8.09% margin) raises concerns. Analyst consensus leans cautious with 44% buy ratings versus 52% hold, suggesting tempered optimism despite recent positive developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GE Aerospace
General Electric Company is a globally diversified technology and financial services company. The Company's products and services include aircraft engines, power generation, water processing, and household appliances to medical imaging, business and consumer financing, and industrial products.
Read more on GE →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
